Pharmacokinetics of chloramphenicol in calves during the first weeks of life

The pharmacokinetics of chloramphenicol, either administered as the monosuccinate ester or as a veterinary formulation, were studied in calves from the first day of life to the age of 10–12 weeks and compared with the results obtained in adult cattle. (1) After intravenous injection of 0.15 mmol/kg chloramphenicol monosuccinate, the plasma elimination half life of intact ester fell from a value of 33 min on the first day of life to 15 min at the age of 10–12 weeks (value in cows = 14 min). Free chloramphenicol reached maximal plasma concentrations after 2–3 h on the first day of life, but in less than 15 min in cows. The elimination half-life fell from about 15 h on day 1 to 4.8 h at the age of 10–12 weeks (4.2 h in cows). The bioavailability of the ester was more than 90% on Day 1, but declined to 50–60% from Day 7 on account of rapid renal excretion: 21–28% of the total dose was excreted as intact ester in a 2 h period following injection in calves aged 10–12 weeks. (2) The veterinary formulation of chloramphenicol proved toxic when administered intravenously at a dose of 0.15 mmol/kg, and even a dose of 0.093 mmol/kg was less well tolerated than 0.15 mmol/kg of the monosuccinate ester. (3) The pharmacokinetics of chloramphenicol fitted an open two-compartment model, the half-life of the elimination phase corresponded well to the values determined in the experiments with the monosuccinate ester. (4) The intramuscular injection of 0.15 mmol/kg of the ester or 0.093 mmol/kg of chloramphenicol provided ‘therapeutic’ plasma concentrations (≥ 5 μg/ml) within 15–30 min and for about 24 h in calves aged 7 days. (5) Chloramphenicol crossed the placenta when given to cows shortly before a Caesarian section, but equilibrium was not reached within 50–100 min. (6) The binding of chloramphenicol to serum proteins was dependent both on total protein and drug concentrations. It rose from less than 30% on day 1 to about 40% in adult cattle. (7) Recommendations for a dosage regime for chloramphenicol in calves are made on the basis of the pharmacokinetic data.     

Carprofen in veterinary medicine. II. Inhibitory effect on the release of PGF2 alpha in the early postpartum cow

Carprofen, a non-steroidal anti-inflammatory drug (NSAID) known to inhibit prostaglandin synthesis, was given intravenously in five cows at a daily dose of 0.7 mg/kg for five days beginning on day 1 postpartum. Blood samples were collected at various times over a period of six days following the first injection. At this dose, carprofen reached highest plasma values of about 45 micrograms/ml after the fifth injection and was well tolerated by all the cows. During the whole experimental period, mean plasma levels of 15-keto-13, 14-dihydro-prostaglandin F2 alpha, the primary metabolite of PGF2 alpha, were significantly (p less than 0.05) lower in treated than in control animals (28-47% vs 64-101% of pretreatment concentrations). The suppressive effect of carprofen on PGF2 alpha-production occurred immediately after its application and was maximal 3-6 h post injection on the first and on the fifth experimental day (60-80% and 40-85%, respectively). We conclude from our results that carprofen in a single dose of 0.7 mg/kg b.w. effectively suppresses PGF2 alpha-release in the postpartum cow. Whether this effect is beneficial in the treatment of uterine inflammatory processes remains to be determined.     

Effects of progesterone and weaning on LH and FSH responses to naloxone in postpartum beef cows

Two experiments were conducted to evaluate the effects of naloxone, an endogenous opioid receptor antagonist, on LH and FSH secretion in postpartum beef cows. In Experiment 1, 24 cows were divided into three equal groups. On day 15 postpartum, all cows were bled for 8 hr at 10 min intervals to evaluate LH secretory parameters. On day 18 postpartum, three treatments were administered: (a) saline at 0730 and 1130 hr; (b) 275 mg naloxone at 0730 and 1130 hr; (c) naloxone as in (b) above, plus this group was also treated with 50 mg progesterone (P4) twice daily from day 16 to day 19. In each treatment, jugular vein samples were collected at 10 min intervals from 0800 to 1600 hr. On day 19 the same treatments were administered at the same times, however, all cows were given 25 micrograms GnRH at 1200 hr to evaluate the LH secretory response. Naloxone increased mean LH concentration (P less than .05) and tended to increase pulse amplitude and frequency compared to controls. However, the most dramatic difference was due to P4 treatment which suppressed mean LH, pulse amplitude and frequency. Treatments had no effect on LH secretion in response to a 25 micrograms dose of GnRH. In Experiment 2, the effects of suckling on the naloxone response were examined in 16 postpartum cows. On day 21 postpartum, blood was collected at 10 min intervals for 8 hr and then calves were removed from half the cows. After 3 days of calf removal, all cows were sampled at 10 min intervals for 4 hr; then naloxone was injected after each 10 min sample at a dose rate of 200 mg/hr (33 mg per injection). Naloxone treatment and sampling continued for an additional 8 hr. Calf removal alone had very little effect on LH pulsatility. However, naloxone resulted in increased pulse frequency and mean LH compared to the control period. We conclude that LH release in the early postpartum cow is partially regulated by endogenous opioid peptides. We were unable to detect any effects on FSH secretion nor on pituitary sensitivity to exogenous GnRH.     

Regulation of bovine labor with a long-acting carba-analog of oxytocin: a preliminary report.

The long-acting oxytocin (OT) analog 1-desamino-1-monocarba-E12-Tyr(OMe)]-OT(dCOMOT) was given IV to 13 pregnant cows near to term, but not in actual labor. The animals were para 1 to 5. Of these cows, four were treated with 20 mg of dexamethoasone 48 hours before the peptide was injected; the remaining nine animals were given no other medication. The animals usually were given a single injection of 5 mg of dCOMOT into the jugular veiw (5 to 7 micrograms/kg of body weight). In those instances where delivery was not complete within six hours, a second injection of peptide was given. In all instances, the first injection initiated labor as judged by the behavior of both uterus and cow. In most instances, there was also intermittent spurting of colostrum from the udder over a six-hour period after injection. In the four cows treated first with dexamethasone, the mean duration of induced labor was 4.35 hours after dCOMOT injection. In the nine non-treated cows, the mean duration of induced labor was 14.25 hours. The difference between the two values was significant. For both groups separately, and all data together, there was a linear inverse relation between the size of the external ostium uteri at injection and the duration of labor after peptide injection. All calves were healthy with no signs of hypoxia and the dose rates used did not result in any instance of uterine tetany or tachyphylaxis.     

Warfarin in the dog: pharmacokinetics as related to clinical response

Warfarin was administered intravenously (i.v.) as a single dose of 1.5 mg/kg to healthy dogs and the pharmacokinetic parameters were investigated. Elimination could be described by a one-compartment open model. Values for the elimination half-life and apparent specific volume of distribution were 14.5 ± 4.1 h and 0.22 ± 0.04 litre/kg, respectively. Oral maintenance doses were calculated from the data collected following i.v. administration and administered every 12 h for a total of five doses after an initial i.v. loading dose of 1.5 mg/kg. Prothrombin times increased from a control value of 8.6 ± 0.3 sec to 55.2 ± 5.2 sec over a period of 96 h. Prothrombin time returned to control values by 62 h after withdrawal of the drug. We propose a dosage regimen of warfarin for anticoagulant therapy in the dog of 0.22 mg/kg to be given orally every 12 h. Prothrombin time should be monitored during therapy and the dose of warfarin modified according to the degree of suppression of coagulation factors desired.     

Excretion of [3H]prednisolone in clinically normal and experimentally infected bovine udders

The excretion rate of [3H]prednisolone from clinically normal and experimentally infected udders of 10 lactating cows was studied. Each quarter of 6 cows was injected with a single dose of [3H]prednisolone mixed with non-radioactive prednisolone equivalent to 10 mg in 10 ml of peanut oil base. Each of the remaining 4 cows was given 40 mg of nonradioactive prednisolone and [3H]prednisolone in 60% ethanol IV. Control and postadministration samples of blood, milk, and urine were examined for radioactivity. The effects of [3H]prednisolone were evaluated in the same cows, first in clinically normal udders, then 2 weeks later in udders experimentally infected with Streptococcus agalactiae. Absorption and elimination of prednisolone were the same before and after induced infection. Within 3 hours after intramammary injection, 95% of the labeled prednisolone was absorbed systemically, less than 5% of this dose was recovered in milk, and 29% was excreted in urine. After IV injection of [3H]prednisolone, less than 0.2% of the total radioactivity was recovered in milk and less than 46% was excreted in urine. Clinical mastitis induced by S agalactiae was moderate. Circulating blood leukocytes and somatic cells in the milk of normal cows remained essentially unchanged. The leukocyte response to induced infection was rapid in blood and milk. Large numbers of leukocytes were noticed in the milk and a severe leukopenia occurred. Prednisolone treatment did not alter the number of somatic cells in milk or reduce the inflammatory response of experimentally infected cows.     

Udder edema in cattle: effect of furosemide, hydrochlorothiazide, acetazolamide, or 50% dextrose on venous blood pressure

Before injection of diuretic drugs, blood pressures were determined in the cranial superficial epigastric veins (milk vein) and jugular veins of 15 Holstein cows with udder edema at parturition and of 15 healthy (control) cows at parturition. Cows with udder edema had a significant (P less than or equal to 0.05) mean increase in cranial superficial epigastric venous pressure at parturition, compared with that of control cows. After IV administration of 500 mg of furosemide in cows with udder edema, the mean cranial superficial epigastric venous blood pressure significantly (P less than or equal to 0.05) decreased within 5 minutes, remained at the decreased pressure for 90 minutes, and then returned to near pretreatment pressures by 210 minutes after furosemide injection; however, furosemide did not significantly affect the jugular venous blood pressure of these cows. Furosemide injection did not significantly affect the cranial superficial epigastric or jugular venous blood pressure in the control cows. After IV administration of hydrochlorothiazide (250 mg), acetazolamide (500 mg), or 50% dextrose (500 g), the cranial superficial epigastric and jugular venous blood pressures in cows with udder edema at parturition were not significantly different from those in cows without udder edema at parturition during the 210-minute evaluation period after injection of the drugs.     

Effective factors for the reduced feed intake of milk cows fed with rations containing urea

In two experiments with milk cows with permanent rumen fistula it was investigated whether, apart from urea being unpalatable, further physiologic parameters are responsible for the reduced feed intake. In experiment I the cows received 2, 3 resp 4% urea orally with barley coarse meal, or an equivalent amount was given continuously from the beginning of the feeding over a period of three hours through the fistula. When 2, 3 resp. 4% urea were given orally, the consumption went down in the first 30 min to 58, 52 resp. 40%. When urea was given rumenally, no depression of the consumption could be observed. There were distinct relations with the NH3-concentration in the rumen fluid. At 20 to 35 mg per 100 ml there was no resp. a slight depressioon only and at 40 mg a significant depression. When the concentration rose to greater than 50 mg, consumption was stopped. In experiment II the rumenal application of urea began two hours before the feeding. The high NH3-level shortly after the beginning of feeding (58 mg/100 ml) caused a stop in the feed consumption. No relation could be observed between the urea concentration in veinous blood and the feed intake.     

The cardiovascular and respiratory effects of medetomidine and thiopentone anaesthesia in dogs breathing at an altitude of 1486 m

The purpose of this study was to evaluate the cardio-respiratory effects of the combination of medetomidine and thiopentone followed by reversal with atipamezole as a combination for anaesthesia in 10 healthy German Shepherd dogs breathing spontaneously in a room at an altitude of 1486 m above sea level with an ambient air pressure of 651 mmHg. After the placement of intravenous and intra-arterial catheters, baseline samples were collected. Medetomidine (0.010 mg/kg) was administered intravenously and blood pressure and heart rate were recorded every minute for 5 minutes. Thiopentone was then slowly administered until intubation conditions were ideal. An endotracheal tube was placed and the dogs breathed room air spontaneously. Blood pressure, pulse oximetry, respiratory and heart rate, capnography, blood gas analysis and arterial lactate were performed or recorded every 10 minutes for the duration of the trial. Thiopentone was administered to maintain anaesthesia. After 60 minutes, atipamezole (0.025 mg/kg) was given intramuscularly. Data were recorded for the next 30 minutes. A dose of 8.7 mg/kg of thiopentone was required to anaesthetise the dogs after the administration of 0.010 mg/kg of medetomidine. Heart rate decreased from 96.7 at baseline to 38.5 5 minutes after the administration of medetomidine (P < 0.05). Heart rate then increased with the administration of thiopentone to 103.2 (P < 0.05). Blood pressure increased from 169.4/86.2 mmHg to 253.2/143.0 mmHg 5 minutes after the administration of medetomidine (P < 0.05). Blood pressure then slowly returned towards normal. Heart rate and blood pressure returned to baseline values after the administration of atipamezole. Arterial oxygen tension decreased from baseline levels (84.1 mmHg) to 57.8 mmHg after the administration of medetomidine and thiopentone (P < 0.05). This was accompanied by arterial desaturation from 94.7 to 79.7% (P < 0.05). A decrease in respiratory rate from 71.8 bpm to 12.2 bpm was seen during the same period. Respiratory rates slowly increased over the next hour to 27.0 bpm and a further increases 51.4 bpm after the administration of atipamezole was seen (P < 0.05). This was maintained until the end of the observation period. Arterial oxygen tension slowly returned towards normal over the observation period. No significant changes in blood lactate were seen. No correlation was found between arterial saturation as determined by blood gas analysis and pulse oximetry. Recovery after the administration of atipamezole was rapid (5.9 minutes). In healthy dogs, anaesthesia can be maintained with a combination of medetomidine and thiopentone, significant anaesthetic sparing effects have been noted and recovery from anaesthesia is not unduly delayed. Hypoxaemia may be problematic. Appropriate monitoring should be done and oxygen supplementation and ventilatory support should be available. A poor correlation between SpO2 and SaO2 and ETCO2 and PaCO2 was found.     

Leucocytic changes in cows given intravenous injections of Escherichia coli endotoxin.

Single intravenous injections of Escherichia coli endotoxin into normal cows produced dose dependent leucocytic and febrile responses. Injections of 5 to 20 microgram endotoxin induced a neutrophilia between 4 and 8 h, whereas 50 to 500 microgram produced a severe neutropenia for 4 to 6 h followed by a gradual increase in neutrophils along with slight to moderate left shift. Higher doses caused progressively severe lymphopenia and greater increase in fever than the lower doses. It was concluded that blood leucocytic changes during the early part of endotoxin-induced mastitis are partly related to systemic absorption of endotoxin, and that the size of the bone marrow neutrophil reserve in the cow could be estimated by injecting 5 to 10 microgram of endotoxin intravenously.     

Effects of endotoxin-induced mastitis on the pharmacokinetic properties of aditoprim in dairy cows.

Plasma disposition of aditoprim, a new dihydrofolate reductase inhibitor, was studied in healthy cows and cows with endotoxin-induced mastitis. A single dose of 5 mg of aditoprim/kg of body weight was administered IV to 5 healthy cows and to the same cows 3 weeks later at 2 hours after intramammary infusion of 0.1 mg of endotoxin into the rear quarters. Mastitis developed in all endotoxin-infused quarters and cows had systemic signs of disease (fever, tachycardia, depression) from 2 to 10 hours after infusion of endotoxin. Pharmacokinetic characteristics of aditoprim in healthy cows were a large volume of distribution (6.28 L/kg), a systemic clearance of 0.82 L/h/kg, and an elimination half-life of 7.26 hours. In cows with mastitis, plasma concentrations of aditoprim were lower between 5 and 26 hours after injection. The systemic clearance (1.00 L/h/kg) and the volume of distribution (12.25 L/kg) were significantly higher in cows with mastitis, but elimination half-life was not significantly different. The lower plasma concentrations of aditoprim between 5 and 26 hours after injection in cows with mastitis are explained by fluid compartment shifts and/or blood flow changes induced by mastitis, although increased elimination of aditoprim in cows with mastitis cannot completely be ruled out. The antibacterial activity of aditoprim is nearly the same as that of trimethoprim. The longer elimination half-life time of aditoprim, however, indicates that it may have a practical pharmacotherapeutic advantage over trimethoprim.     

Guaifenesin alone or in combination with ketamine or sodium pentobarbital as an anesthetic in rabbits.

Guaifenesin was administered alone and in combination with ketamine or sodium pentobarbital to adult New Zealand white rabbits. A solution of 5% guaifenesin in 5% dextrose given intravenously at a dosage of 200 mg/kg, abolished the pedal, palpebral and corneal reflexes for up to 15 minutes with little influence on cardiopulmonary function. Guaifenesin (200 mg/kg, intravenously) and ketamine (50 mg/kg, intramuscularly) produced effective and safe surgical anesthesia for over 30 minutes. This combination mildly depressed respiratory rate but heart rate and arterial blood pressure were not significantly affected. Guaifenesin (200 mg/kg, intravenously) was combined with sodium pentobarbital (20 mg/kg, intravenously) to produce surgical anesthesia for a period of more than 30 minutes. This combination depressed respiratory rate, produced a tachycardia and decreased arterial blood pressure.     

Pharmacokinetics and tissue residues of gentamicin in lactating cows after multiple intramuscular doses are administered

Gentamicin was administered IM to 6 healthy, mature, lactating cows at a dosage of 3.5 or 5 mg/kg of body weight every 8 hours for 10 consecutive days (total, 30 doses). Endometrial biopsies were done at 72, 136 or 144, and 216 hours after the first dose was administered. On the 10th day, just before the last dose of gentamicin was administered, blood samples (designated 10th-day base-line samples) were obtained, and serial blood samples were obtained for 144 hours after the last injection was given. The cows were catheterized on the 10th day, and urine was obtained for 10 to 18 consecutive hours. Milk samples were also obtained. The cows were slaughtered at different times after the last dose was given, and samples were taken from 22 tissues and organs. Serum, milk, urine, and tissue gentamicin concentrations were determined by radioimmunoassay. Serum gentamicin concentrations were best fitted to a 2-compartment open model. The mean half-lives for absorption, distribution, and elimination were 0.16 +/- 0.14, 2.59 +/- 0.53, and 44.91 +/- 9.38 hours, respectively. Total body clearance and renal clearance were 1.65 +/- 0.69 and 1.32 +/- 0.25 ml/min/kg, respectively. The percentage of the dose excreted unchanged in the urine at 8 hours after the last dose was given was 98 +/- 15. As expected, of the tissues examined, the gentamicin concentrations in the kidney cortex and medulla were 1,500 times greater than those in serum. Renal function remained within the baseline range during the 10 days of gentamicin treatment.(ABSTRACT TRUNCATED AT 250 WORDS)     

Hemodynamics in the guinea pig after anesthetization with ketamine/xylazine

The resting hemodynamics were determined in 8 guinea pigs after they were anesthetized with ketamine/xylazine. Measurements were made of blood pressure, heart rate, cardiac output, arterial blood gases, and pH. These measurements were obtained initially at 4 to 5 hours after an injection (IM) of ketamine HCl (25 mg) and xylazine (0.15 mg) was given to anesthetize the animals for catheterization (period 1), again 5 days after the operation (period 2), and finally 4 to 5 hours after a 2nd injection of ketamine/xylazine (period 3). There were no differences in heart rates, respiratory rates, or cardiac outputs among the 3 study periods. However, arterial blood pressure was slightly, but significantly, lowered after, and presumably due to, instrumentation (62 +/- 4 mm of Hg, P less than 0.05) when compared with the 5-day postoperative period (67 +/- 7 mm of Hg) or after the readministration of anesthetics (66 +/- 7 mm of Hg). The partial pressure of carbon dioxide in the arterial blood was slightly lower (4 mm of Hg, P less than 0.05) in both acutely postanesthetic periods (period 1 and period 3) than in the same animals at postoperative day 5 (period 2). This study has demonstrated that resting hemodynamics measured shortly after this anesthesia with ketamine/xylazine are not largely different from those in chronically instrumented animals.     

Effect of Kisspeptin on Regulation of Growth Hormone and Luteinizing Hormone in Lactating Dairy Cows

Kisspeptin (KP),a neuroendocrine regulator of reproduction,is hypothesized to be an integrator of metabolism and hormones critical to the regulation of reproduction.Lactation is associated with enhanced growth hormone (GH) responsiveness and reduced fertility.Our study was designed to determine the effects of lactation on KP-stimulated GH and luteinizing hormone (LH) secretion.Five nonlactating and five lactating dairy cows were used in the study.Experiments were conducted with lactating cows at weeks 1,5 and 11 after parturition.The experimental treatments (saline and KP [ 100 and 400 pmol/kg body weight] ) were given intravenously and blood was collected and plasma was stored until later assay to determine concentrations of GH,LH,progesterone and non-esterified fatty acids.We found that neither dose of KP stimulated an increase in GH secretion.The low dose of KP increased (P ＜0.05)LH concentrations only in lactating cows.The higher dose of KP elicited an increase in circulating LH concentrations in both lactating and non-lactating cows.The lower dose of KP increased ( P ＜ 0.05 ) the area under the curve for LH only in cows during week 5 of lactation,and the area under the curve of LH following the highest dose of KP was greater ( P ＜ 0.05 ) in cows during week 5 of lactation than that for the other groups of cows.In summary,lactation status and stage of lactation did not change the sensitivity of the GH system to KP.However,an effect of stage of lactation on KP-stimulated LH secretion was detected in the dairy cows.Study of the KP system during lactation in dairy cows may provide critical insights into the mechanisms for lactation-associated changes in the reproductive axis.     

乳黄消散对靶动物奶牛的安全性试验

为了确定乳黄消散在奶牛临床上使用的安全剂量,筛选出20头健康奶牛随机分为4组,每组5头,即0倍剂量组(对照组)、1倍推荐剂量组、3倍推荐剂量组和5倍推荐剂量组,每天1次,经口灌服给药连用5d。试验期间,观察受试奶牛的精神状态,采食饮水,眼角、肛门有无污秽物等临床症状,并检测给药后0、3、5d的体温、血常规和生化指标。结果显示,给药后每组奶牛的精神状态良好,采食饮水正常,眼角、肛门无污秽物,且与对照组相比,不同剂量的乳黄消散对受试奶牛的体温、血液生理学指标差异均不显著(P>0.05);给药后第3天,Ⅲ组的ALB、AST、ALT、ALP、LDH、CK和CRE水平显著升高(P<0.05);给药后第5天,ALB、AST、ALT、ALP、LDH、CK、UREA和CRE水平显著升高(P<0.05)。说明乳黄消散至少3倍推荐剂量口服给药对靶动物奶牛是安全的,但5倍推荐剂量对靶动物奶牛的肝、肾有损伤。     

Decreased sedation by xylazine and high blood pressure in cows with BSE.

Fifteen cows with bovine spongiform encephalopathy (BSE) and 90 healthy cows were given xylazine intramuscularly at a dosage of 0.15 mg/kg bodyweight. The onset of sedation and of drooling was recorded, and the heart and respiratory rates and the systolic and diastolic blood pressure were measured every five minutes for 40 minutes. All the healthy cows but only five of the 15 cows with BSE became sedated, and the period between the administration of xylazine and the onset of sedation was twice as long in the cows with BSE than in the healthy cows (15.0 [7.5] and 7.6 [2.6] minutes). Throughout the observation period, the blood pressure of the cows with BSE was significantly higher than that of the healthy cows, and the blood pressure of the healthy cows, but not of the cows with BSE, decreased significantly towards the end of the observation period.     

SYNCHRONISATION OF OESTRUS IN BEEF CATTLE ARTIFICIAL BREEDING PROGRAMS USING PROSTAGLANDIN F2α

PGF2α either as a subcutaneous injection (8 or 10 mg) or intrauterine infusion (dose 5 mg) successfully synchronised oestrus in beef cattle AI programs. The beef cattle programs were managed by 1 of the following 2 systems.

• 1 Two 10-day insemination periods, 1 for the first and the second for the repeat inseminations. Oestrus was detected and oestrus cows inseminated for the first 4 days of the first period. On the fifth day all cows not inseminated were treated with PGF2α. The treated cattle came into oestrus and were inseminated over the following 2 to 5 days.
• 2 Two PGF2α treatments 10 days apart followed by two 4-day insemination periods. During the first 4-day period, cows exhibiting synchronised oestrus were inseminated. Cows returning to oestrus were inseminated during the second 4-day period, about 18 days after the first period.

Synchronisation of oestrus was not sharp, oestrus being distributed over 7 days, with the majority of cows being in oestrus on the third (42.3%) and fourth (22.4%) days. The route of administration of PGF2α (injection or infusion) did not effect oestrus synchronisation. PGF2α by either route of administration did not effect the fertility of cows inseminated at either the synchronised or subsequent oestrus. Pregnancy rates at the synchronised oestrus were higher when cows were inseminated after detection of oestrus than when they were inseminated without reference to oestrus at a fixed time 3 days after PGF2α treatment (mass injection). Oestrus synchronisation greatly reduced the input of time, labour and feed required during the total program. However, oestrus synchronisation did not alter the overall efficiency of artificial breeding programs measured in terms of the proportion of cattle entering a program that were inseminated and became pregnant. The main problem encountered was drug wastage through unknowingly treating cows and heifers that were not cycling.     

Treatment of parturient paresis with high-dose calcium

The goal of the present study was to evaluate a calcium dose that was higher than the conventional dose for treatment of parturient paresis in cows. Thirty cows with parturient paresis received 1000 ml of 40 per cent calcium borogluconate solution supplemented with 6 per cent magnesium hypophosphite. Cows in group A received 200 ml of the solution intravenously over a 10-minute period, and the remaining 800 ml via a slow intravenous drip over a six-hour period. Cows in group B received 500 ml of the solution intravenously over a 20-minute period, and the remaining 500 ml via a slow intravenous drip over a six-hour period. Afterwards, the cows were monitored continuously and examined every hour for eight hours. Samples of blood were collected from all the cows before treatment and at 10, 20, 40, 60, 90, 120, 180, 240, 300, 360, 420 and 480 minutes and 24, 48 and 72 hours after treatment. The concentrations of total calcium, ionised calcium, inorganic phosphorus and magnesium were determined. Cows that did not stand within 12 hours of treatment received one or more additional treatments. There was no significant difference in the recovery rate between the two groups. Of the 30 cows, 14 (47 per cent) rised after one treatment and 15 others (50 per cent) were cured after two or more treatments. One cow did not respond to repeated treatments and was euthanased four days after the start of treatment. The results of electrolyte analyses before treatment did not differ significantly between the two groups. In 27 (90 per cent) cows, the concentrations of calcium and inorganic phosphorus were lower than normal and in 3 (10 per cent) cows, only the concentration of inorganic phosphorus was lower than normal.The concentration of total calcium increased markedly ten minutes after the start of treatment in both groups, and at eight hours, the mean concentration of calcium was within the normal range. At 24 and 48 hours, the mean concentration of calcium was below normal, but at 72 hours it was again within the normal range. The concentration of inorganic phosphorus increased slowly in both groups, although it was not within the normal range at eight hours. In both groups, it achieved normal values at 24, 48 and 72 hours.The mean electrolyte concentrations did not differ significantly at any measuring point between cows that stood within eight hours of treatment and those that did not. Our results indicate that increasing the dose of calcium administered does not improve the recovery rate of cows with parturient paresis.     

Reversal of xylazine-induced sedation in dairy calves with atipamezole: A field trial

Dairy calves immobilized with xylazine (XYL) were given atipamezole-HCl (ATI) at different XYL:ATI dose ratios (w/w) for reversal and the antagonistic effect of xylazine was evaluated. Control animals received saline for comparison. Intramuscular administration of xylazine (0.139–0.357 mg/kg) induced sedation with complete immobilization in all animals (n=195) and there were no spontaneous recoveries before injection of atipamezole or saline. Atipamezole was given 10–81 min and saline 25 min after xylazine administration. Intramuscular administration of atipamezole at XYL:ATI dose ratios of 5:2 (n=11), 10:3 (n=21), 4:1 (n=21) and 5:1 (n=25) effectively antagonized the xylazine-induced immobilization and sedation. The mean times (standard deviation) from injection of atipamezole until the animals were standing for these dose ratio groups were 6.09 (3.12), 5.15 (2.87), 6.35 (2.54) and 7.86 (3.11) min, respectively. The mean time to standing for control animals (n=11) was 94.1 (3.0) min. Intravenous administration of atipamezole at XYL:ATI dose ratios of 10:3 (n=7), 4:1 (n=33), 5:1 (n=16), 8:1 (n=27) and 10:1 (n=9) rapidly reversed the xylazine-induced immobilization and sedation. The mean times (standard deviation) from injection of atipamezole until the animals were standing for these dose ratio groups were 0.98 (0.22), 1.32 (0.48), 1.09 (0.34), 1.39 (0.52) and 1.60 (0.69) min, respectively. The mean time to standing for control animals (n=14) was 88.1 (13.1) min.Animals given high doses of atipamezole (dose ratio groups 5:2 intramuscularly, 10:3 intravenously and 4:1 intravenously) showed signs of excitement while in animals given low doses of atipamezole (dose ratio groups 5:1 intramuscularly and 10:1 intravenously) resedation and relapse into recumbency occurred. Medium doses of atipamezole (dose ratio groups 10:3 intramuscularly, 4:1 intramuscularly, 5:1 intravenously and 8:1 intravenously) did not cause any undesirable side-effects or resedation, and can be recommended for reversal of xylazine-induced sedation in dairy calvesAbbreviations ATI atipamezole-HCl - BW body weight - IM intramuscular - IV intravenous - SD standard deviation - XYL xylazine